Change in the Chief Financial Officer at Biotest AG

EQS-News: Biotest AG / Key word(s): Personnel
Change in the Chief Financial Officer at Biotest AG
12.09.2024 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Change in the Chief Financial Officer at Biotest AG

• Martin Möller to assume role of Chief Financial Officer (CFO) on the Management Board for 6 months starting September 14

Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal Zubiaga, is leaving the company for personal reasons. We would like to thank Ms. Mendizabal Zubiaga for her tireless efforts and dedication. The entire team wishes her every success and all the best for her future professional and personal endeavors.

As part of this change, we welcome Mr. Martin Möller (52) as the new Interim Chief Financial Officer. Mr. Möller will assume this position for the next six months, effective September 14, 2024 and will be responsible for the
CFO-activities of the company during this period. We are pleased to have Mr. Möller on board as an experienced leader to support us during this transition period.

The company would like to thank both individuals and looks forward with confidence to the next six months under Mr. Möller's leadership.

About Biotest

Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com).

IR contact

Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: ir@biotest.com

PR contact

Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

12.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com